50 research outputs found
Imunoterapija karcinoma mokraÄnog mjehura
Urothelial urinary bladder carcinoma represents 9th most common malignancy in the world. This disease is held responsable for more than 165000 deaths throughout the world. In the past 30 years there were no major advances in treatment of this tumor. Chemotherapy regimens used for treatment are based on platinum compounds. In a recent time a series of immune system modulating drugs have been developed. This drugs have achieved excellent results in the treatment of urinary bladder carcinoma.Karcinom mokraÄnog mjehura je deveti najÄeÅ”Äi maligni tumor u svijetu. Bolest je uzrok viÅ”e od 165.000 smrtnih sluÄajeva. U posljednjih 30 godina nije bilo veÄih pomaka u moguÄnostima lijeÄenja ovoga tumora. Kemoterapijski protokoli za lijeÄenje uznapredovale ili metastatske bolesti mokraÄnog mjehura bazirani su uglavnom na spojevima platine. U posljednje vrijeme razvijen je niz novih lijekova koji moduliraju imunoloÅ”ki odgovor organizma na tumorske stanice i time omoguÄavaju uspjeÅ”no lijeÄenje karcinoma mokraÄnog mjehura
Evaluation of Adjuvant Chemotherapy in Patients with Colorectal Cancer in Primorsko-goranska and Istarska County ā A Twenty Years Retrospective Study
Colorectal cancer is the second most common malignant disease in developed countries, with about one million new
cases worldwide every year, accompanied with high mortality rate. We examined the survival rate and recurrence (occurrence
of distant metastases and/or local recurrence) of patients with colorectal cancer in Primorsko-Goranska and Istarska
County who received adjuvant chemotherapy, compared to those who did not in the period since 1980. until 1999.
This study involves 483 patients with colorectal cancer stages II and III of Primorsko-Goranska and Istarska County,
which were underwent curative resections of colorectal cancer at the Clinical Hospital Centre Rijeka, and then treated
with chemotherapy (288) or without Chemotherapy (195). We analyzed the five year survival rate and the recurrence of
malignant disease in the adjuvant treatment group in comparison with not treated group with chemotherapy, depending
on the stage of disease, degree of histological differentiation, patient age and location of cancer (colon or rectum). After
follow-up of 60 months died 44.79% (129/288) of patients who received chemotherapy and 53.33% (104/195) of patients
who did not receive chemotherapy. The relative risk of death (from any cause) in chemotherapy-treated group versus the
group without chemotherapy was 0.82 (p<0.008). Recurrence of malignant disease in the chemotherapy group was
38.54% (111/288), and in the group without chemotherapy was 46.15% (90/195). The relative risk of recurrence of malignant
disease in the chemotherapy group versus the group without chemotherapy was 0.78 (p<0.001). There was no difference
in treatment efficacy regard to the localization of the tumor, but there were differences in efficiency with respect to
disease stage, grade and age. Chemotherapy with 5-fluorouracil and leukovorin ameliorate the survival and reduces recurrence
and distant metastases in patients with colorectal cancer stages II and III
The Ā»Round BlockĀ« Surgical Technique in the Management of Multicentric Fibroadenomas
The Ā»round blockĀ« surgical technique in the treatment of a female patient with multiple, multicentric fibroadenomas
in both breasts is presented. The advantages of this technique for patients with multicentric benign breast lesions are
minimal postoperative scar and a favourable aesthetic result. Breast dimensions and the areolar diameter were measured
in 203 subjects of Primorsko-goranska county during examination in the Out-Patient Hospital for Breast Diseases,
including the operated patient. Smaller breast dimensions and a larger areolar diameter provide an easier access to any
part of the breast due to a smaller distance between the incision and a fibroadenoma and a larger circumference of circular
periareolar incision, thus facilitating the surgery. The analysis of average, maximum and minimum values measured
shows that the Ā»round blockĀ« technique can be performed in all cases of multiple and multicentric fibroadenomas
regardless of breast size, areolar diameter and the location of fibroadenoma in the breast
The Ā»Round BlockĀ« Surgical Technique in the Management of Multicentric Fibroadenomas
The Ā»round blockĀ« surgical technique in the treatment of a female patient with multiple, multicentric fibroadenomas
in both breasts is presented. The advantages of this technique for patients with multicentric benign breast lesions are
minimal postoperative scar and a favourable aesthetic result. Breast dimensions and the areolar diameter were measured
in 203 subjects of Primorsko-goranska county during examination in the Out-Patient Hospital for Breast Diseases,
including the operated patient. Smaller breast dimensions and a larger areolar diameter provide an easier access to any
part of the breast due to a smaller distance between the incision and a fibroadenoma and a larger circumference of circular
periareolar incision, thus facilitating the surgery. The analysis of average, maximum and minimum values measured
shows that the Ā»round blockĀ« technique can be performed in all cases of multiple and multicentric fibroadenomas
regardless of breast size, areolar diameter and the location of fibroadenoma in the breast
Imunoterapija karcinoma mokraÄnog mjehura
Urothelial urinary bladder carcinoma represents 9th most common malignancy in the world. This disease is held responsable for more than 165000 deaths throughout the world. In the past 30 years there were no major advances in treatment of this tumor. Chemotherapy regimens used for treatment are based on platinum compounds. In a recent time a series
of immune system modulating drugs have been developed. This drugs have achieved excellent results in the treatment of urinary bladder carcinoma.Karcinom mokraÄnog mjehura je deveti najÄeÅ”Äi maligni tumor u svijetu. Bolest je uzrok viÅ”e od 165.000 smrtnih sluÄajeva. U posljednjih 30 godina nije bilo veÄih pomaka u moguÄnostima lijeÄenja ovoga tumora. Kemoterapijski protokoli za lijeÄenje uznapredovale ili metastatske bolesti mokraÄnog mjehura bazirani su uglavnom na spojevima platine. U posljednje vrijeme razvijen je niz novih lijekova koji moduliraju imunoloÅ”ki odgovor organizma na tumorske stanice i time omoguÄavaju
uspjeÅ”no lijeÄenje karcinoma mokraÄnog mjehura
Imunoterapija karcinoma mokraÄnog mjehura
Urothelial urinary bladder carcinoma represents 9th most common malignancy in the world. This disease is held responsable for more than 165000 deaths throughout the world. In the past 30 years there were no major advances in treatment of this tumor. Chemotherapy regimens used for treatment are based on platinum compounds. In a recent time a series of immune system modulating drugs have been developed. This drugs have achieved excellent results in the treatment of urinary bladder carcinoma.Karcinom mokraÄnog mjehura je deveti najÄeÅ”Äi maligni tumor u svijetu. Bolest je uzrok viÅ”e od 165.000 smrtnih sluÄajeva. U posljednjih 30 godina nije bilo veÄih pomaka u moguÄnostima lijeÄenja ovoga tumora. Kemoterapijski protokoli za lijeÄenje uznapredovale ili metastatske bolesti mokraÄnog mjehura bazirani su uglavnom na spojevima platine. U posljednje vrijeme razvijen je niz novih lijekova koji moduliraju imunoloÅ”ki odgovor organizma na tumorske stanice i time omoguÄavaju uspjeÅ”no lijeÄenje karcinoma mokraÄnog mjehura
Aksilarnu limfadenektomiju trebalo bi izostaviti kod bolesnica sa karcinomom dojke i minimalnom rezidualnom bolesti u sentinel limfnom Ävoru nakon neoadjuvantnog sistemskog lijeÄenja
Background: In modern breast cancer management, SLNB is a standard of care. For the patients with limited sentinel lymph node involvement in the upfront surgery setting, ALND can be safely omitted. However, for any sentinel node metastasis detected following neoadjuvant systemic treatment (NST), ALND is still considered a mandatory procedure.
Patients and methods: Present retrospective analysis has included all breast cancer patients submitted to surgery following NST in Clinical Hospital Centre (CHC) Rijeka in the period from 2017 till 2020.
Results: SLNB was performed in 151 of 222 consecutive patients, and sentinel node metastasis was detected in 49 cases. The risk of non-sentinel lymph node involvement in sentinel node-positive patients was 34.7%, but exclusively for cases with macro-metastatic disease detected in the sentinel node. In addition, for the patients diagnosed with clinically uninvolved axilla, the risk of ypN2-3 status was only 2.8%.
Conclusions: ALND following NST is overtreatment in 65.3% of sentinel node-positive patients. Axillary irradiation with the omission of ALND should be considered for the sentinel-positive patients with only micro-metastatic disease detected in the sentinel node following neoadjuvant chemotherapy, as well as for those with low volume macro metastatic disease, diagnosed with the uninvolved axilla.Uvod: U modernom kirurÅ”kom pristupu lijeÄenja kacinoma dojke SLNB je univerzalno prihvaÄeni standard. Izostavljanje ALND, u sluÄajevima sa metastazom pronaÄenom u do dva sentinel limfna Ävora, ne utjeÄe na onkoloÅ”ke ishode kod primarno kirurÅ”ki lijeÄenih pacijentica, MeÄutim, svaka metastaza detektirana u sentinel limfnom Ävoru nakon provedenog neoadjuvantnog sistemskog lijeÄenja joÅ” uvijek se smatra apsolutnom indikacijom za ALND.
Pacijenti i metode: Sve pacijentice operirane zbog karcinoma dojke u KliniÄkom BolniÄkom Centru (KBC) Rijeka nakon provedene neoadjuvantne kemoterapije, u periodu od 2017. do 2020., ukljuÄene su u ovu retrospektivnu analizu.
Rezultati: SLNB je uÄinjena kod 151 od 222 uzastopne pacijentice, a metastaza u sentinel Ävoru pronaÄena je u 49 sluÄajeva. Rizik metastatske bolesti u ne-sentinel limfnim Ävorovima kod sentinel-pozitivnih pacijentica je 34.7%, meÄutim iskljuÄivo u sluÄajevima sa makrometastazom u sentinel Ävoru. Nadalje, kod skupine pacijenica dijagnosticiranih sa kliniÄki i radioloÅ”ki negativnom aksilom, rizik od ypN2-3 statusa je samo 2.8%
ZakljuÄak: Nakon neoadjuvantne kemoterapije ALND je overtreatment u 65.3% sentine-pozitivnih pacijentica. Izostavljanje ALND uz zraÄenje aksile nakon provedenog neoadjuvantnog lijeÄenja je opcija koju bi trebalo razmotriti za sentinelpozitivne bolesnice sa mikro-metastazom u sentinel Ävoru, kao i za bolesnice sa malim volumenom makrometastatske bolesti u sentinel limfnim Ävorovima, a koje su inicijalno dijagnosticirane sa kliniÄki negativnom aksilom
Operabilni invazivni karcinom dojke u eri konzervativne kirurgije; retrospektivna analiza 5-godiŔnjeg preživljenja i kontrole bolesti
Background: Following breast cancer treatment recommendations, the conservative approach is accepted and highly respected in the Clinical Hospital Center (CHC) Rijeka. However, we have found that institutional follow-up data are lacking. This retrospective analysis aims to update institutional data on survival and disease control rates.
Methods: From 2011 till 2014, 915 breast cancer patients underwent surgery at CHC Rijeka, and 615 were included in this analysis. The Institutional Ethics Committee approved the analysis.
Results: All patients were female, and the average age was 59 years. In the 5-year postoperative period, local, regional, and distant recurrence-free survival rates and overall survival and disease-free survival were calculated. All rates negatively correlate with a higher T and N status and a higher stage of the disease. The analysis has also demonstrated that in the pT1-3 pN0-1 subgroup, sentinel lymph node biopsy (SLNB) was not inferior to axillary lymph node dissection (ALND) in terms of locoregional control of disease and overall survival.
Conclusion: Besides updating institutional data, the analysis confirmed that overall survival and locoregional control of the disease in the upfront-surgery patients are similar between pN0 and pN1 subpopulations and between pN2 and pN3, but statistically significantly different between pN0-1 and pN2-3. Currently ongoing, prospective observational multicenter clinical trial aims to translate the significance of these results into the neoadjuvant era.Uvod: Temeljem suvremenih preporuka za lijeÄenje karcinoma dojke, u KliniÄkom bolniÄkom centru (KBC) Rijeka prihvaÄa se i zagovara konzervativni kirurÅ”ki pristup. MeÄutim, na razini naÅ”e institucije, ali i na nacionalnom nivou, malo je obraÄenih rezultata lijeÄenja. Cilj ove retrospektivne analize je ažuriranje institucionalnih podataka o preživljenju i kontroli
bolesti.
Metode: U periodu od 2011. do 2014. godine, u KBC Rijeka operirano je 915 pacijentica oboljelih od karcinoma dojke, a njih 615 ukljuÄeno je u ovu analizu. Istraživanje je odobreno od EtiÄkog povjerenstva KBC Rijeka.
Rezultati: Sve su pacjentice bile žene, prosjeÄno stare 59 godina. IzraÄunate su ukupne stope preživljenja bez lokalnog, regionalnog i udaljenog recidiva, te stope ukupnog preživljenja i preživljenja bez povrata bolesti u petogodiÅ”njem postoperativnom periodu. Sve su stope u negativnoj korelaciji sa viÅ”im T i N statusom kao i viÅ”im stadijem bolesti. Osim navedenog, rezultati su potvrdili da je biopsija sentinel limfnog Ävora ekvivalentna aksilarnoj disekciji u smislu lokoregionalne kontrole bolesti kao i ukupnog petogodiÅ”njeg preživljenja u pT1-3 pN0-1 podskupini.
ZakljuÄak: Osim ažuriranja podataka naÅ”e institucije, ova je analiza potvrdila da su stope preživljenja i lokoregionalne kontrole bolesti u eri primarnog kirurÅ”kog tretmana sliÄne izmeÄu pN0 i pN1 subpopulacija kao i meÄu pN2 i pN3, meÄutim statistiÄki znaÄajno razliÄite izmeÄu pN0-1 I pN2-3 podskupina. Prospektivno, opservacijsko, multicentriÄno kliniÄko istraživanje koje je u tijeku pokuÅ”ava istražiti znaÄenje ovih rezultata u neoadjuvantoj eri
Imunoterapija karcinoma mokraÄnog mjehura
Urothelial urinary bladder carcinoma represents 9th most common malignancy in the world. This disease is held responsable for more than 165000 deaths throughout the world. In the past 30 years there were no major advances in treatment of this tumor. Chemotherapy regimens used for treatment are based on platinum compounds. In a recent time a series
of immune system modulating drugs have been developed. This drugs have achieved excellent results in the treatment of urinary bladder carcinoma.Karcinom mokraÄnog mjehura je deveti najÄeÅ”Äi maligni tumor u svijetu. Bolest je uzrok viÅ”e od 165.000 smrtnih sluÄajeva. U posljednjih 30 godina nije bilo veÄih pomaka u moguÄnostima lijeÄenja ovoga tumora. Kemoterapijski protokoli za lijeÄenje uznapredovale ili metastatske bolesti mokraÄnog mjehura bazirani su uglavnom na spojevima platine. U posljednje vrijeme razvijen je niz novih lijekova koji moduliraju imunoloÅ”ki odgovor organizma na tumorske stanice i time omoguÄavaju
uspjeÅ”no lijeÄenje karcinoma mokraÄnog mjehura
Treatment of kidney cancer ā oncological approach
Napredak u razumijevanju i poznavanju molekularnih puteva rasta i razvoja tumora bubrega doveo je do razvoja Äitavog niza lijekova kojima je danas moguÄe lijeÄiti oboljele od ove bolesti. Brojne kliniÄke studije dokazale su uÄinkovitost novih terapija. Svakodnevna primjena posljednjih dostignuÄa svjetske znanosti omoguÄava ostvarenje jednog od primarnih onkoloÅ”kih ciljeva, a to je izljeÄenje pacijenata ili pretvaranje ove teÅ”ke bolesti u dugotrajnu kroniÄnu bolest.Improvement in knowledge of molecular pathways of growth and developement of malignant kidney cancer has led to development of a number of efficient drugs. In this way the treatment of this condition nowadays is possible and successfull as documented by many clinical trials. New ways of treating kidney cancer tend to fulfill primary oncology goals which are to cure completely the patient or to make this serious disease a longlasting chronic disease